Literature DB >> 17548033

Clinical presentation and management of carcinoid tumors.

Matthew H Kulke1.   

Abstract

The generally indolent nature of neuroendocrine tumors is an advantage in the management of patients who have localized disease, and surgery alone is often curative. This same property presents a challenge in the treatment of patients who have metastatic disease, in whom standard cytotoxic chemotherapy has a limited benefit. In such patients, the use of somatostatin analogs, interferon, and the treatment of hepatic metastases may provide effective palliation. The highly vascular nature of carcinoid tumors has led to the investigation of antiangiogenic agents in this setting. Preliminary reports of activity associated with agents targeting the vascular endothelial growth factor pathway suggest that such strategies may play a role in the future treatment of patients who have this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17548033     DOI: 10.1016/j.hoc.2007.04.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  23 in total

1.  Primary carcinoid tumour of the liver in a young Filipino female.

Authors:  Margarita Victoria Holgado-Galicia; Karla Maria P Nomorosa; Ena Lyn R Ang; Frances Lina Lantion-Ang
Journal:  BMJ Case Rep       Date:  2011-02-14

2.  Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.

Authors:  Ikechukwu Akunyili; Monica T Garcia-Buitrago; Jessica Macintyre; Joe Levi; Caio M Rocha Lima
Journal:  J Gastrointest Oncol       Date:  2011-06

Review 3.  Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Authors:  Talal Hilal
Journal:  Ther Adv Med Oncol       Date:  2016-11-17       Impact factor: 8.168

4.  Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.

Authors:  Joseph D Valentino; Jing Li; Yekaterina Y Zaytseva; W Conan Mustain; Victoria A Elliott; Ji Tae Kim; Jennifer W Harris; Katherine Campbell; Heidi Weiss; Chi Wang; Jun Song; Lowell Anthony; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2014-01-17       Impact factor: 12.531

Review 5.  Treatment of liver metastases in patients with digestive neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Matilde Pia Spampatti; Dario Conte; Clorinda Ciafardini; Federica Cavalcoli; Maddalena Peracchi
Journal:  J Gastrointest Surg       Date:  2012-07-25       Impact factor: 3.452

6.  Gastric carcinoid tumors.

Authors:  Russell Wardlaw; James W Smith
Journal:  Ochsner J       Date:  2008

7.  A study of pipeline drugs in neuroendocrine tumors.

Authors:  Catherine T Anthony; Juan G Bastidas; Jessica L Thomson; John Lyons; James M Lewis; Joshua E Schwimer; Peter Casey; Jennifer Abadie; Daniel J Frey; Yi-Zarn Wang; J Philip Boudreaux; Eugene A Woltering
Journal:  J Gastrointest Cancer       Date:  2012-06

8.  Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.

Authors:  Yeting Du; Monica Ter-Minassian; Lauren Brais; Nichole Brooks; Amanda Waldron; Jennifer A Chan; Xihong Lin; Peter Kraft; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2016-08       Impact factor: 5.678

Review 9.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

10.  An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Authors:  Kanika A Bowen; Scott R Silva; Jessica N Johnson; Hung Q Doan; Lindsey N Jackson; Pat Gulhati; Suimin Qiu; Taylor S Riall; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.